News und Analysen

Waters Corporation (NYSE:WAT) today released its 2022 Environmental, Social, and Governance (ESG) Report highlighting the company’s efforts for 2021 and the first half of 2022 to reduce its

CenterWell Senior Primary Care will open three new senior-focused primary care centers in Louisville through mid-2023, marking the company’s debut in Kentucky and giving local seniors access to

Agilent Technologies Inc. (NYSE: A) has become a member of How2Recycle®, a standardized labeling system owned by Delaware nonprofit Green Blue Institute, Inc. The program involves a coalition of

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced updated data from a Phase 2/3 clinical trial demonstrating a robust neutralizing immune response one-month after a 30-µg

Pfizer Inc. (NYSE:PFE) today announced its investigational cancer immunotherapy, elranatamab, received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for the

QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and

Agilent Technologies Inc. (NYSE: A) today announced it will release financial results for the fourth quarter of fiscal year 2022 after the stock market closes on Monday, Nov. 21. The company will

Pfizer Inc. (NYSE: PFE) reported solid financial results for third-quarter 2022 and updated certain components of 2022 financial guidance⁽⁴⁾. Pfizer raised the lower end of its 2022 revenue

Pfizer Inc. (NYSE: PFE) today announced positive top-line data from the Phase 3 clinical trial (NCT04424316) MATISSE (MATernal Immunization Study for Safety and Efficacy) investigating its bivalent

DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended September 30, 2022.

Third Quarter 2022 Financial Highlights:

• 
  Revenue grew 18% versus the same

Labcorp (NYSE: LH), a leading global life sciences company, today announced results for the third quarter ended Sept. 30, 2022, and updated full-year guidance.

"Labcorp made important strategic

Kidney care provider Monogram Health and leading health and well-being company Humana Inc. (NYSE: HUM) have announced a new value-based care agreement for most Humana Medicare Advantage HMO and PPO

Leading health and well-being company Humana Inc. (NYSE: HUM) is offering Medicare Advantage plans for the first time in two new states and 140 new U.S. counties, expanding cost-effective health

Pfizer Inc. (NYSE: PFE) will share data across its expansive infectious disease portfolio, including company-sponsored and collaborative research studies, spanning both licensed and investigational

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced early data from a Phase 2/3 clinical trial (NCT05472038) evaluating the safety, tolerability, and immunogenicity of the

QuidelOrtho Corporation (NASDAQ: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) for a 10-µg booster dose of their

Agilent Technologies Inc. (NYSE: A) today announced the opening of the Dissolution Center of Excellence (CoE) facility in Craven Arms, United Kingdom. The newly modernized premises will house the

Humana Inc. (NYSE: HUM) and USAA Life Insurance Company (USAA Life) announced a new Medicare Advantage plan designed with veterans in mind to provide a robust coverage option that complements

Agilent Technologies Inc. (NYSE: A) today announced the World Economic Forum’s Global Lighthouse Network has named Agilent’s facility in Singapore a Fourth Industrial Revolution (4IR) leader for

Pfizer Inc. (NYSE: PFE) announced today the completion of its acquisition of Global Blood Therapeutics, Inc. (GBT), a biopharmaceutical company dedicated to the discovery, development and delivery

Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 TALAPRO-2 study of TALZENNA^® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination

Pfizer Inc. (NYSE: PFE) announced today the completion of its acquisition of Biohaven Pharmaceutical Holding Company Ltd., the maker of NURTEC® ODT (rimegepant), an innovative migraine therapy

Agilent Technologies Inc. (NYSE: A) today announced the release of its enhanced 8700 LDIR Chemical Imaging System, which has been further optimized for the analysis of microplastics in

The Humana Foundation, the philanthropic arm of Humana Inc. (NYSE: HUM), is donating $1 million towards relief and recovery efforts for those impacted by Hurricane Ian in Florida and Hurricane